Recently, PTPN11 (SHP2), a non-receptor type PTP, was reported to play an oncogene-like role in laryngeal cancer, hepatocellular carcinoma and glioblastoma, and the mechanism appeared to involve dephosphorylating RAS to activate the RAS/ERK pathway42–44. The gene discussed is MAPK1; the disease is hepatocellular carcinoma.